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To assess the level of activity and toxicity of gefitinib (ZD1839, Iressat) in a population of patients with locally recurrent and/or
metastatic head and neck cancer. Patients were recruited into an expanded access programme through the multidisciplinary head and
neck clinics at the Royal Marsden and St George’s Hospitals. Patients were required to have received at least one course of standard
systemic chemotherapy or radiation therapy, or be medically unfit for chemotherapy. Patients were commenced on single-agent
gefitinib at a dose of 500mgday
 1. Clinical, symptomatic and radiological response, time to progression (TTP), survival and toxicity
were recorded. A total of 47 patients were enrolled (35 male and 12 female) with a median age of 62 years (range 18–93 years).
The observed clinical response rate was 8% with a disease control rate (complete response, partial response, stable disease) of 36%.
In all, 34% of patients experienced an improvement in their symptoms. The median TTP and survival were 2.6 and 4.3 months,
respectively. Acneiform folliculitis was the most frequent toxicity observed (76%) but the majority of cases were grade 1 or 2. Only
four patients experienced grade 3 toxicity of any type (all cases of folliculitis). Gefitinib was well tolerated and yielded symptomatic
improvement in one-third of patients. However, this agent appeared to possess limited antitumour activity in this group of patients
with head and neck cancer in whom the objective response rate, median TTP and survival were all lower than has been reported in a
previous study.
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Head and neck cancer is the sixth most common malignant
tumour diagnosed in Europe. More than 100000 cases were
diagnosed in Europe in 2000 with more than 50000 deaths
occurring in the same year. Many patients present with locally
advanced, unresectable (stages III and IV) disease in which the
standard treatment is a combination of platinum-based chemo-
therapy and radiotherapy. For patients who relapse after such
treatment, the only curative treatment option is surgical. If this is
not possible, as is often the case, platinum-based chemotherapy is
frequently used as palliative therapy (Forastiere et al, 1992; Jacobs
et al, 1992) Other drugs that have some activity in this tumour type
include bleomycin, methotrexate, taxanes, gemcitabine and
vinorelbine (Clark et al, 2001; Basaran et al, 2002). However,
tumour response rates rarely exceed 30–35% (Liggett and
Forastiere, 1995) and responses are usually of short duration such
that the outlook in the setting of recurrent/metastatic disease is
poor, with 1-year survival below 30% and median survival only 4
months. Treatment options for patients with progressive disease
(PD) are limited and, therefore, this is an area of high unmet need.
The epidermal growth factor receptor (EGFR), a member of the
erbB family of receptors, is a transmembrane glycoprotein whose
intracellular domain has tyrosine kinase activity. Activation of the
EGFR increases the proliferation, differentiation and survival of
cancer cells via multiple phosphorylation-dependent signalling
cascades down to transcription factors in the nucleus. Epidermal
growth factor receptor is expressed at low levels on the surface of
normal cells. However, it is implicated in the development of
various malignancies and is overexpressed in 30% of human solid
tumours and up to 90% of squamous cell cancers of the head and
neck (Dassonville et al, 1993). Epidermal growth factor receptor is
also implicated in angiogenesis, ability to metastasise, and inhibition
of apoptosis (Baselga, 2000; Shintani et al, 2003a,b) Indeed, EGFR
expression has been found to relate closely to prognosis in head and
neck cancer, higher levels correlating with poorer progression-free
and overall survival (Nicholson et al,2 0 0 1 ) .
Gefitinib (ZD1839, Iressat) is an orally active, selective EGFR-
tyrosine kinase inhibitor that blocks the signal transduction
pathways described above. In human head and neck cancer cell
lines it has been shown to inhibit cell proliferation in a dose-
dependent manner (Di Gennaro et al, 2003; Shintani et al, 2003a,b)
In addition, Iressa has been shown to have antimetastatic
properties in human head and neck, and breast cancer cells
(Mandal et al, 2002).
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sFour phase I studies (Baselga et al, 2002; Herbst et al, 2002;
Ranson et al, 2002; Nakagawa et al, 2003) have evaluated gefitinib
in more than 250 patients, of whom 28 had head and neck cancer.
Gefitinib was well tolerated at doses from 150 to 800mgm
 2, the
most frequent grade 1 or 2 toxicities being diarrhoea (47–55%),
asthenia (44%) and an acneiform follicular rash (46–64%).
Antitumour activity, including both partial responses (PRs) and
cases of prolonged stable disease (SD), was observed at all doses.
Clinically meaningful SD was achieved in 50% of patients with
head and neck cancer, and quality of life (QoL) ratings also
remained stable during treatment, except in one study where they
improved significantly over time (LoRusso et al, 2003).
A phase II study has evaluated oral gefitinib (500mgday
 1)a s
first- or second-line monotherapy in 52 patients with recurrent or
metastatic head and neck cancer most of whom had previously
received combination chemotherapy or radiotherapy (Cohen et al,
2003a,b). Of these, 47 patients were evaluable for tumour response
and an objective PR rate of 10.6% (one complete response) was
demonstrated. Disease control, defined as objective tumour
response plus SD, was achieved in 53% of patients and was
sustained for more than 6 months in 13% of patients. The response
rates and survival times of patients who received gefitinib as first-
line therapy were not significantly different to those of patients
who had received prior chemotherapy. Overall, the median times
to progression and death were 3.4 and 8.1 months, respectively,
with an estimated 1-year survival of 29%. These results are more
favourable than those achieved with chemotherapy in this setting,
but with the additional benefit of reduced treatment-related
toxicity. There was only a single case of grade 4 toxicity
(hypercalcaemia), a 4–6% incidence of grade 3 toxicity (anorexia,
diarrhoea, nausea and hypercalcaemia), grade 1 or 2 skin rash in
48% and grade 1 or 2 diarrhoea in 50%.
In July 2002, AstraZeneca plc opened an expanded access
programme to provide single-agent gefitinib to patients with
locally advanced, relapsed or metastatic head and neck cancer.
Patients were eligible if they had failed standard treatment, or were
not fit enough to receive other systemic anticancer therapy. We
report our experience in using this agent in this patient group.
PATIENTS AND METHODS
Eligibility criteria
Patients with recurrent or metastatic head and neck cancer were
recruited into this expanded access programme through the
multidisciplinary head and neck clinics at the Royal Marsden and
St George’s Hospitals. Patients were eligible for recruitment if they
had had a previous histologically or cytologically confirmed
squamous cell cancer of the head and neck. Patients with recurrent
and/or metastatic disease were eligible for treatment if they had
received previous systemic chemotherapy and/or radiotherapy or
were ineligible or unfit for such therapy. There was no requirement
for patients to have a specific life expectancy. Patients were excluded
if they were suitable for further radiotherapy, chemotherapy, or
other systemic anticancer medication or had participated in a
previous blinded study involving gefitinib. Patients with incomplete
wound healing from prior oncological or other major surgery were
also excluded. The presence of another significant clinical disorder
or laboratory finding or evidence of clinically active interstitial lung
disease was also considered as an exclusion criterion. In general,
these inclusion criteria permitted entry of a number of patients with
very poor prognosis disease.
Treatment plan and dose modification
Gefitinib was initially administered by mouth at a total dose of
500mg once daily. Patients who were unable to swallow were
allowed to dissolve the tablets in water, and to have this solution
delivered via nasogastric, gastrostomy or jejunostomy tube.
Therapy was continued until disease progression, concomitant
illness preventing further administration, unacceptable toxicity, or
patient withdrawal. Dose reduction to 250mg was permitted if
toxicity became unacceptable to the patient with the option to
increase the dose again if the toxicity improved. Toxicity was
graded using the National Cancer Institute Common Toxicity
Criteria version 2.0. These doses were selected in the absence of
specific data on a dose–response relationship in head and neck
cancer, although data from the randomised IDEAL1 study in
patients with lung cancer demonstrated no difference between 250
and 500mg (Fukuoka et al, 2003).
Response assessment
Patients were assessed clinically and radiologically prior to
commencing gefitinib and were subsequently assessed clinically
on a monthly basis, with radiological assessment, where possible,
at 8–12 weeks. Patients were imaged using the same modality as
used at baseline. Radiological response guidelines as defined by the
Response Evaluation Criteria in Solid Tumours (RECIST) were
used, defining responses after at least 8 weeks of therapy as either a
complete response (CR), a PR, SD or PD. Disease control was
defined as the sum of patients achieving a CR, PR or SD.
Confirmation of responses was required after 12 weeks. With
respect to clinical response, the RECIST criteria were applied to
visible or palpable areas of disease and CR, PR, SD or PD was
recorded. In addition, an assessment of symptomatic response was
made using a four-point scale previously reported in adenoid
cystic carcinoma and non-small-cell lung cancer (Hardy et al,
1989; Hill et al, 1997). In this scale, individual symptoms were
documented prior to treatment, and at subsequent assessment
each symptom was recorded as being either (a) worse, (b)
unchanged, (c) improved or (d) resolved. A subjective response
in a particular symptom was defined as (c) or (d). The overall best
symptom control was evaluated for each patient and if multiple
symptoms responded differentially then the results were inter-
preted as follows: ‘no change’ þ ‘worse’ scored ‘worse’; ‘no
change’ þ ‘better’ scored ‘better’; and ‘better’ þ ‘worse’ scored
‘no change’. No attempt was made to measure QoL using a
validated questionnaire for patients with head and neck cancer. All
cases of clinical or radiological response or SD were reviewed by
three observers.
Statistical analysis
The primary end points were response rate and time to
progression (TTP). Secondary end points included survival and
toxicity. Time to progression and survival were measured from the
date of commencing Iressa until disease progression or death,
respectively, and were summarised by Kaplan–Meier curves. Data
were updated to September 2004.
RESULTS
Prior therapy
A total of 47 patients were enrolled in the extended access
programme from March 2003 to June 2004. Their characteristics
and prior therapy are shown in Table 1. Gefitinib was administered
orally in 46 cases (98%) and via a gastrostomy tube in one patient
(2%). In all, 18 (38%) patients had received prior platinum-based
chemotherapy in the context of radical chemoradiotherapy at some
point in their treatment. Seven (15%) of these had also received
further palliative systemic therapy (including platins, 5-fluoro-
uracil, taxanes and triapine (a novel ribonucleotide reductase
inhibitor)) prior to commencing gefitinib. Nine (19%) patients had
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the same agents, prior to commencing gefitinib. Only four (9%)
patients received gefitinib as first-line therapy, the majority (35,
74%) receiving it as second- or third-line therapy, with eight (17%)
receiving it as their fourth to seventh line of treatment. Follow-up
continued after disease progression until death. Only three patients
(6%) received subsequent systemic therapy, two with platinum-
based chemotherapy and one within a phase I trial of systemic
administration of an oncolytic virus.
Response assessment
Treatment responses are summarised in Table 2. In terms of
objective clinical response, four (8%) patients achieved a PR, and
13 (28%) had SD as their best response, such that the disease
control rate was 36%. Response to treatment was not related to
prior therapy. Those who responded all had locally recurrent
disease at the time of commencing gefitinib (one in the
nasopharynx, two in the region of the pinna and one in the floor
of mouth). All four patients subsequently progressed locally with
no evidence of systemic metastatic disease. Radiological assess-
ment was performed in only 22 (47%) of patients, largely due to
the rapidly progressive nature of the disease in the majority of the
remaining patients. A total of 17 patients (36%) progressed and
died prior to the 8-week assessment with a further three (6%)
having been too unwell to attend their follow-up and imaging
appointments. One patient had mucosal disease that was not
assessable by imaging, and four patients did not undergo imaging
despite having radiologically assessable disease. These results
reflect the reality of treating a group of patients with end-stage
head and neck cancer in whom performance status and disease
activity can change rapidly. One PR was observed (2%), and 12
patients (26%) had SD, giving a radiological disease control rate of
28%. Of the patients with SD, seven had local recurrence at
presentation, of whom five subsequently progressed locally with
no evidence of metastatic disease and two have not yet progressed.
Five patients had metastatic disease at the time of commencing
gefitinib and all have since progressed. There was a reported
improvement in symptoms in 16 (34%) patients and there was no
change in a further five (11%) patients. There was symptomatic
deterioration in 26 (55%) of patients.
Survival data
In total, 44 of the 47 patients have developed PD. Three patients
remain on gefitinib with SD. The median TTP was 2.6 months
(range 0–9 months). The median survival was 4.3 months (range
0–13months). The median follow-up time was 5 months (range
2–9 months). Of the 47 patients, eight were still alive at the time of
analysis. Figures 1 and 2 show the Kaplan–Meier curves for
progression-free and overall survival. Univariate analysis showed
that stage of disease was the only significant factor affecting
progression-free survival (see Table 3).
Table 1 Patient characteristics
Patients
Characteristic No. %
Total 47 100
Male 35 74
Female 12 26
Age (years)
Median 62
Range 18–93
Disease at time of commencing IRESSA
Locally recurrent 29 62
Metastatic
a 18 38
Histology
Squamous cell carcinoma 45 96
UCNT
b 12
Carcinosarcoma 1 2
ECOG performance status
00 0
12 6 5 5
21 9 4 0
32 4
Prior therapy (n¼43)
Surgery 22 51
Radiotherapy 40 93
With chemotherapy 18 42
Alone (radical or palliative) 22 51
Chemotherapy 27 63
Radical chemoradiation only 11 26
Radical chemoradiation and then for recurrence or metastases 7 16
Only for recurrent disease or metastases 9 21
aThese patients may also have had local recurrence simultaneously with metastatic
disease.
bUndifferentiated carcinoma of nasopharyngeal type.
Table 2 Response
N %
Clinical response (objective)
CR 0 0
Partial response 4 8
Stable disease 13 28
Progressive disease 30 64
Radiological response (RECIST)
CR 0 0
PR 1 2
SD 12 26
PD 9 19
nd 25 53
Symptom response (best)
(d) Resolved 0 0
(c) Improved 16 34
(b) Unchanged 5 11
(a) Worse 26 55
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Figure 1 Progression-free survival.
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Toxicity data and dose reductions are summarised in Table 4. In
all, 34 patients were assessable for toxicity. Of the 13 (28%)
patients in whom toxicities were not documented, nine died before
their scheduled outpatient visit, one deteriorated and missed the
scheduled visit, two were admitted to other hospitals and no
toxicity was documented, and one patient was lost to follow-up.
Skin toxicity in the form of an acneiform folliculitis usually
affecting the face (65% of those affected) and trunk (42% of those
affected) was the most frequently observed side effect. Of the 26
patients affected, 20 experienced grade 1–2 skin reactions with
only four patients experiencing a grade 3 reaction. Folliculitis was
the commonest reason for dose reduction. Diarrhoea (grade 1–2)
affected 16 (47%) of the patients in whom toxicities were recorded.
Fatigue and anorexia were reported in a few cases, and one patient
experienced plantar-palmar erythema. No patient experienced
treatment-related lung toxicity and no grade 4 toxicity of any type
was observed.
A dose reduction from 500 to 250mg per day was made in 14
(30%) of the patients. In all but two of these patients (both with
grade 2 folliculitis), the side effects improved. Gefitinib was
stopped temporarily in three patients with folliculitis and after
resolution of symptoms was restarted at a dose of 250mg. One
patient was admitted to another centre with an episode of
supraventricular tachycardia of uncertain aetiology. In this patient,
gefitinib was stopped and not restarted due to simultaneous
demonstration of PD on imaging investigations.
DISCUSSION
This is the second report on the use of gefitinib in locally
advanced, recurrent or metastatic head and neck cancer and,
despite the fact that it represents a single institutional study of
relative small numbers of patients, we believe that it provides
important further clinical information in this area. Owing to the
nature of the extended access programme under which the drug
was made available, there was no scope for inclusion of a control
arm (placebo, best supportive care or alternative systemic
therapy). This issue is currently being addressed in a randomised
trial of gefitinib vs methotrexate.
The objective clinical response rate was only 8.4%, less than the
radiologically confirmed 10.6% response rate reported in the only
other published study of this agent in patients with head and neck
cancer (Cohen et al, 2003a,b) This study also reports a reduced
median TTP (2.6 vs 3.4 months) and median survival (4.3 vs 8.1
months) compared to the previous report. The survival rate at 12
months was 29% in Cohen’s series, compared to 0% in this study.
The reasons for these differences may be explained in terms of the
characteristics of the patients in the two studies. In general, the
patients reported here represented a group with a very poor
prognosis in whom palliative chemotherapy was not an option.
The patients in our study were more likely to have locally recurrent
disease (62 vs 44%) and have a poorer performance status (PS 0: 0
vs 21%, PS 1: 55 vs 62%, PS 2: 40 vs 17% and PS 3: 4 vs 0%). Many
of our patients had rapidly progressing disease at the time of
commencing gefitinib, as demonstrated by the number of patients
who progressed before the first scheduled radiological assessment.
More patients in Cohen’s study had been fit to receive prior
therapy, especially surgery (89 vs 51%) and chemotherapy (85 vs
63%), underscoring the fact that more of the patients recruited to
our programme had never been fit enough to receive radical
treatment.
The obvious attraction of using gefitinib in this group of
patients (in the absence of other available therapeutic manoeuvres)
was the ease of oral administration and the predicted lack of
significant toxicity. In this study, the toxicity of palliative gefitinib
was mild, although the folliculitis previously reported with
gefitinib was more prevalent and florid than has been previously
reported. Facial rash was a frequent cause of patients feeling
self-conscious about their appearance and a rash affecting the
trunk or limbs was frequently pruritic. The impact of the
cutaneous rash on the QoL of patients has not been formally
assessed in this study but it is noteworthy that the only reason for
dose reduction in 11 patients was folliculitis, and that it was a
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Figure 2 Overall survival.
Table 3 Univariate analysis of (a) progession-free survival and (b) overall
survival
n Hazard ratio (95% CI) P-value
(a)
Gender
Female 12 1 0.7
Male 35 1.15 (0.5–2.29) —
Age
Per year 47 1 (0.99–1.02) 0.75
Line of therapy
First 21 1 0.35
Second+ 26 0.75 (0.4–1.38) —
Stage
Local disease 11 1 0.03
Nodal7distant mets 36 2.52 (1.09–5.77)
PS
1 18 1 0.13
2 or above 29 1.6 (0.86–2.97) —
(b)
Gender
Female 12 1 0.81
Male 35 1.1 (0.49–2.45) —
Age
Per year 47 1.01 (0.99–1.03) 0.41
Line
First 21 1 0.06
Second+ 26 0.51 (0.25–1.02) —
Stage 11 1 0.27
Local disease 36 1.61 (0.69–3.73) —
Nodal7distant mets
PS
1 18 1 0.1
2 or above 29 1.84 (0.89–3.82) —
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scontributory factor in another two patients. It has previously
been suggested that the folliculitis associated with gefitinib may be
a marker of treatment outcome (Perez-Soler, 2003). Our data
provide some support for this conclusion in that four of the 14
patients who required a dose reduction had a PR and the other 10
had SD. However, in this group of patients, it is also possible
that the association of response with skin rash is a reflection
of the fact that patients who responded or who had SD were
likely to have been taking the drug long enough to develop the
side effect, whereas the nonresponders tended to stop taking
gefitinib early. Diarrhoea and fatigue were mild and infrequent
and generally managed by simple antidiarrhoeal medication.
There was no evidence of pulmonary toxicity in this group of
patients. Despite the apparent lack of activity of this agent, 21
(45%) patients reported stabilisation or improvement of disease-
related symptoms on treatment. It is worth bearing this figure in
mind when considering the use of gefitinib as a palliative therapy
in patients with head and neck cancer. However, given that the
objective response rate is inferior to that reported for platinum-
based chemotherapy in this context, the latter should remain the
standard of care in this setting for those patients who are fit
enough to tolerate such therapy.
In the last 2 years a number of studies have begun to shed light on
factors that predict the probability of response to gefitinib in
patients with lung cancer. In particular, it appears that patients with
mutations in exons 18–21 of the EGFR gene (corresponding to the
ATP binding site) are more likely to respond to treatment (Paez
et al, 2004). These mutations have been identified predominantly in
patients with adenocarcinoma but similar mutations have been
identified in two patients with squamous cell lung cancers (Kim
et al, 2005). Recently, deletions in exon 19 have been reported in
three of 41 Korean patients with squamous cell cancer of the head
and neck (Lee et al, 2005). These discoveries have given renewed
impetus to the prospect of using gefitinib (and related drugs) in
patients with head and neck cancer. However, as with other targeted
therapies, it is likely that if gefitinib does find a role it will be in
combination with established therapies, such as chemotherapy and
radiotherapy in patients with newly diagnosed disease. In addition
to other agents that target the EGFR pathway (erlotinib, cetuximab),
gefitinib will have to be considered alongside a plethora of novel
agents directed against a variety of cellular targets. In particular,
agents that target different growth factor receptors, the angiogenic
switch and the apoptotic pathway appear to hold great promise in
the treatment of head and neck cancer.
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